High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
DOI:
https://doi.org/10.2340/actadv.v104.40913Keywords:
melanoma, BRAF V600, MAPKi, biomarkerAbstract
The prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain. The association was retrospectively analysed between BRAF V600 mutation level (defined as the ratio of the quantification of the BRAF V600 allele to the percentage of tumoral cells in the sample analysed) and progression-free and overall survival (PFS and OS, respectively) and 3-month response rate in a cohort of 58 patients with metastatic melanoma who harboured BRAF V600E/K mutations and received dual targeted-therapy BRAF/MEK inhibitors. The BRAF mutation level cut-off determined by the area under the receiver operating characteristic curve after internal validation by bootstrap methods was 0.44. Risk of poor PFS and OS was associated with BRAF V600 mutation level > 0.44 on multivariate analysis (p = 0.02 and p = 0.02, respectively) after adjusting for major confounding factors (age, sex, lactate dehydrogenase level, brain metastasis, and treatment line). No association was found between BRAF mutation level and 3-month response rate. Our study shows that high BRAF V600 mutation level in melanoma tissue was associated with poor prognosis in patients with metastatic melanoma treated with BRAF and MEK inhibitors.
Downloads
References
Schummer P, Schilling B, Gesierich A. Long-term outcomes in BRAF-mutated melanoma treated with combined targeted therapy or immune checkpoint blockade: are we approaching a true cure? Am J Clin Dermatol 2020; 21: 493-504.
https://doi.org/10.1007/s40257-020-00509-z DOI: https://doi.org/10.1007/s40257-020-00509-z
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun 2024; 15: 146.
https://doi.org/10.1038/s41467-023-44475-6 DOI: https://doi.org/10.1038/s41467-023-44475-6
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO Guideline Update. J Clin Oncol 2023; 41: 4794-4820.
https://doi.org/10.1200/JCO.23.01136 DOI: https://doi.org/10.1200/JCO.23.01136
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381: 626-636.
https://doi.org/10.1056/NEJMoa1904059 DOI: https://doi.org/10.1056/NEJMoa1904059
Stagni C, Zamuner C, Elefanti L, Zanin T, Bianco PD, Sommariva A, et al. BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK Inhibitors. Mol Cancer Ther 2018; 17: 1332-1340.
https://doi.org/10.1158/1535-7163.MCT-17-1124 DOI: https://doi.org/10.1158/1535-7163.MCT-17-1124
Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, et al. BRAFV600 mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Res 2014; 24: 415-418.
https://doi.org/10.1097/CMR.0000000000000088 DOI: https://doi.org/10.1097/CMR.0000000000000088
Mandalà M, Palmieri G, Ludovini V, Baglivo S, Marasciulo F, Castiglione F, et al. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors. J Eur Acad Dermatol Venereol 2023; 37: 1991-1998.
https://doi.org/10.1111/jdv.19281 DOI: https://doi.org/10.1111/jdv.19281
Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, et al. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget 2015; 6: 37895-37905.
https://doi.org/10.18632/oncotarget.5634 DOI: https://doi.org/10.18632/oncotarget.5634
Mesbah Ardakani N, Leslie C, Grieu-Iacopetta F, Lam WS, Budgeon C, Millward M, et al. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma. Pigment Cell Melanoma Res 2017; 30: 233-242.
https://doi.org/10.1111/pcmr.12569 DOI: https://doi.org/10.1111/pcmr.12569
Tonella L, Pala V, Ponti R, Rubatto M, Gallo G, Mastorino L, et al. Prognostic and predictive biomarkers in stage III melanoma: current insights and clinical implications. Int J Mol Sci 2021; 22: 4561.
https://doi.org/10.3390/ijms22094561 DOI: https://doi.org/10.3390/ijms22094561
Soria X, Vilardell F, Maiques Ó, Barceló C, Sisó P, de la Rosa I, et al. BRAFV600E mutant allele frequency (MAF) influences melanoma clinicopathologic characteristics. Cancers (Basel) 2021; 13: 5073.
https://doi.org/10.3390/cancers13205073 DOI: https://doi.org/10.3390/cancers13205073
Sevilla A, Morales MC, Ezkurra PA, Rasero J, Velasco V, Cancho-Galan G, et al. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma. PLoS One 2020; 15: e0230136.
https://doi.org/10.1371/journal.pone.0230136 DOI: https://doi.org/10.1371/journal.pone.0230136
Berrino E, Balsamo A, Pisacane A, Gallo S, Becco P, Miglio U, et al. High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open 2021; 6: 100133.
https://doi.org/10.1016/j.esmoop.2021.100133 DOI: https://doi.org/10.1016/j.esmoop.2021.100133
Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 2nd ed. Cham, Switzerland: Springer; 2019: p. 104-111.
Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V, et al. Comparison of BRAF mutation screening strategies in a large real-life series of advanced melanoma patients. J Clin Med 2020; 9: 2430.
https://doi.org/10.3390/jcm9082430 DOI: https://doi.org/10.3390/jcm9082430
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Ariane Fizazi, Chris Serrand, Alexandre Evrard, Blanche Bergeret, Pierre-Emmanuel Stoebner, Myriam Marque
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
